We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Placental Cells Secrete Factors That Protect Nerves from Ischemic Damage

By LabMedica International staff writers
Posted on 25 Jan 2015
Print article
Image: Pluristem technicians produce PLacental eXpanded (PLX) cells in the company\'s state-of-the-art facility (Photo courtesy of Pluristem Therapeutics).
Image: Pluristem technicians produce PLacental eXpanded (PLX) cells in the company\'s state-of-the-art facility (Photo courtesy of Pluristem Therapeutics).
Cells derived from placenta have been found to protect PC12 cells—rat-derived cells that behave similarly to and are used as stand-ins to study human nerve cells—in a culture-based ischemic stroke model.

The placenta contains mesenchymal-like adherent stromal cells, which are known to have significant therapeutic potential. These cells are thought to promote tissue repair by secreting biologically active substances including cytokines that modulate immune response and factors that enhance the growth of blood vessels.

The Israeli biotechnology company Pluristem Therapeutics (Haifa, Israel) utilizes placental cells obtained following scheduled caesarean section births. These cells are expanded in the company's state-of-the-art manufacturing facility following current Good Manufacturing Practices in proprietary bioreactor systems that create a three-dimensional microenvironment. This three-dimensional technology allows for the controlled, large-scale growth of cells implementing an optimized, standardized, scaled-up and fully automated operation. This procedure enables mass-production of PLacental eXpanded (PLX) cells with batch-to-batch consistency for a fraction of the cost of traditionally expanding cells using culture dishes.

Investigators from Pluristem in cooperation with colleagues from the Hebrew University of Jerusalem (Israel) and The Weizmann Institute of Science (Rehovot, Israel) investigated the neuroprotective effects of PLX cells using an established ischemic model of nerve growth factor (NGF)-differentiated PC12 cells exposed to oxygen and glucose deprivation followed by reperfusion.

They reported in the February 2015 online issue of the journal Biochimica et Biophysica Acta - Molecular Cell Research that under optimal conditions, PLX cells, added in a trans-well system, conferred 30%–60% neuroprotection to PC12 cells subjected to ischemic insult. PC12 cell death, measured by LDH (lactate dehydrogenase) release, was reduced by PLX cells or by conditioned medium derived from PLX cells exposed to ischemia, suggesting the active release of factorial components.

Since neuroprotection is a prominent function of the cytokine IL-6 and the angiogenic factor VEGF165, the investigators measured their secretion using selective ELISAs of the cells under ischemic or normal oxygenation conditions. IL-6 and VEGF165 secretion by co-culture of PC12 and PLX cells was significantly higher under ischemic compared to normal oxygenation conditions. Furthermore, exogenous supplementation of IL-6 and VEGF165 to insulted PC12 cells conferred neuroprotection, reminiscent of the neuroprotective effect of PLX cells or their conditioned medium.

“These latest findings also call to mind two earlier preclinical studies,” said Zami Aberman, CEO of Pluristem Therapeutics, “which indicated that PLX cells may be an effective treatment for both neuropathic and inflammatory nerve pain, suggesting that PLX cells could be a potential treatment for chronic nerve pain resulting from conditions such as diabetic neuropathy.”

Related Links:

Pluristem Therapeutics 
The Hebrew University of Jerusalem
The Weizmann Institute of Science


New
Gold Member
Syphilis Screening Test
VDRL Antigen MR
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
Newborn Screening Test
NeoMass AAAC 3.0
New
Herpes Virus Test
Human Herpes Virus (HHV-6) Real Time PCR Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.